The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019 : A critical appraisal of the current evidence
© 2021 Wiley Periodicals LLC..
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a major pandemic. While vaccine development moves forward, optimal treatment continues to be explored. Efforts include an ever-expanding number of clinical trials along with newly proposed experimental and off-label investigational therapies; one of which is therapeutic plasma exchange (TPE). There have been a number of publications on TPE use as adjunctive therapy for coronavirus disease 2019 (COVID-19), but no prospective randomized controlled trials (RCTs) have been completed. This article critically appraises the current available evidence on TPE as a treatment modality for SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of clinical apheresis - 36(2021), 3 vom: 01. Juni, Seite 483-491 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Wen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 07.07.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jca.21883 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32138296X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32138296X | ||
| 003 | DE-627 | ||
| 005 | 20231225175705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jca.21883 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM32138296X | ||
| 035 | |a (NLM)33578448 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Wen |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019 |b A critical appraisal of the current evidence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a major pandemic. While vaccine development moves forward, optimal treatment continues to be explored. Efforts include an ever-expanding number of clinical trials along with newly proposed experimental and off-label investigational therapies; one of which is therapeutic plasma exchange (TPE). There have been a number of publications on TPE use as adjunctive therapy for coronavirus disease 2019 (COVID-19), but no prospective randomized controlled trials (RCTs) have been completed. This article critically appraises the current available evidence on TPE as a treatment modality for SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a plasma exchange | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Kelley, Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Deanna C |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Sarita |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Young |e verfasserin |4 aut | |
| 700 | 1 | |a Paroder, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Tanhehco, Yvette |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Minh-Ha |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, Huy P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical apheresis |d 1993 |g 36(2021), 3 vom: 01. Juni, Seite 483-491 |w (DE-627)NLM012676969 |x 0733-2459 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:3 |g day:01 |g month:06 |g pages:483-491 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jca.21883 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 3 |b 01 |c 06 |h 483-491 | ||